HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RIBOLIFE-B

60.250

-1.550-2.51%

Volume:184.63K

Turnover:11.05M

Market Cap:10.24B

PE:-28.69

High:61.500

Open:60.600

Low:58.300

Close:61.800

52wk High:95.800

52wk Low:43.600

Shares:170.00M

HK Float Shares:170.00M

Volume Ratio:0.45

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.100

ROE:-17.59%

ROA:-3.85%

PB:5.08

PE(LYR):-28.69

PS:18.91

Loading ...

Overview Company News Filings

RIBOLIFE-B Reports 2025 Revenue of Approximately 1.485 Billion Yuan, Up 4.1% Year-on-Year

RIBOLIFE-B Appoints Anders Gabrielsen as Chief Medical Officer

Ribo Life Science Names New Chief Medical and Business Officers, Effective 25 March 2026

Bulletin Express

Suzhou Ribo Life Science Co Ltd - FY Revenue RMB148.5 Mln

THOMSON REUTERS

Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million

Suzhou Ribo Life Science Attends RNA Leaders Europe Conference in Vienna

Suzhou Ribo Life Science to present ex-hepatic siRNA delivery data at RNA Leaders Europe Conference

RIBOLIFE-B (06938) Sets 25 Mar 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend

Bulletin Express

Suzhou Ribo Life Science to hold board meeting to approve 2025 annual results and consider final dividend

RIBOLIFE-B (06938) Announces Increase in Issued H Shares Following Over-Allotment Exercise

Bulletin Express

Citigroup Initiates Coverage on RIBOLIFE-B with Buy Rating, Sets HK$102 Target Price

Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial

MT Newswires Live

Suzhou Ribo Life Science (6938) Announces Phase III Clinical Trial Launch for RBD7022 Injection in China

Bulletin Express

RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia

Suzhou Ribo Life Science Co - Phase Iii Clinical Trial of Rbd7022 Injection for Treatment of Hyperlipidemia to Be Initiated in China

THOMSON REUTERS

Suzhou Ribo to start China Phase III trial of RBD7022 for hyperlipidemia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/06938/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":60.25,"timestamp":1788163726690,"preClose":61.8,"halted":0,"volume":184625,"delay":0,"changeRate":-0.02508090614886727,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"Closed","change":-1.55,"latestTime":"08-31 16:08:46","open":60.6,"high":61.5,"low":58.3,"amount":11052216,"amplitude":0.05178,"askPrice":60.3,"askSize":200,"bidPrice":60.2,"bidSize":1400,"shortable":0,"etf":0,"ttmEps":-1.149,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":5,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":61.8,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.451422,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170000000,"roa":"-3.85%","roe":"-17.59%","lyrEps":-2.100221,"volumeRatio":0.451422,"shares":170000000,"dividePrice":0,"high":61.5,"amplitude":0.05178,"preClose":61.8,"low":58.3,"week52Low":43.6,"pbRate":"5.08","psRate":"18.91","week52High":95.8,"institutionHeld":0,"latestPrice":60.25,"committee":0.75,"eps":-2.100221,"divideRate":0,"volume":184625,"delay":0,"ttmEps":-1.149,"open":60.6,"prevYearClose":57.97,"prevWeekClose":61.8,"prevMonthClose":47.16,"prevQuarterClose":46.9,"fiveDayClose":61.4,"twentyDayClose":46.64,"sixtyDayClose":55.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"06938","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787794200000,"name":null,"time":"","dateTimestamp":1787760000000,"actualEps":null},{"market":"HK","date":"2026-03-25","symbol":"06938","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774368000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1784476800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-08-28","current":-52.436902,"percent":0,"low":-53.27383,"twenty":-37.770699,"median":-30.842167,"eighty":-26.562391,"high":-23.913403,"avg":-32.410788,"sd":6.666018,"marketCap":10540293438},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-27","current":-30.985978,"twenty":-48.084787,"median":-40.112534,"eighty":-38.372934,"marketCap":9755740852},{"date":"2026-04-02","current":-34.881193,"twenty":-47.185618,"median":-39.757485,"eighty":-36.526858,"marketCap":11034902677},{"date":"2026-04-10","current":-37.770699,"twenty":-46.28708,"median":-39.613953,"eighty":-36.479378,"marketCap":12041176646},{"date":"2026-04-17","current":-35.241421,"twenty":-45.408639,"median":-38.832211,"eighty":-35.918978,"marketCap":11239568569},{"date":"2026-04-24","current":-33.421304,"twenty":-43.677981,"median":-38.300657,"eighty":-35.241421,"marketCap":10659681875},{"date":"2026-04-30","current":-32.557368,"twenty":-42.07346,"median":-37.836456,"eighty":-34.614071,"marketCap":10386794019},{"date":"2026-05-08","current":-32.498031,"twenty":-41.169053,"median":-37.354591,"eighty":-33.058756,"marketCap":10403849510},{"date":"2026-05-15","current":-32.120533,"twenty":-40.738524,"median":-36.586666,"eighty":-32.493391,"marketCap":10310044309},{"date":"2026-05-22","current":-30.090442,"twenty":-40.591323,"median":-35.918978,"eighty":-32.095834,"marketCap":9636352415},{"date":"2026-05-29","current":-30.88841,"twenty":-40.296947,"median":-35.448939,"eighty":-31.691849,"marketCap":9926295762},{"date":"2026-06-05","current":-28.193848,"twenty":-40.051892,"median":-35.061307,"eighty":-30.899503,"marketCap":9073521212},{"date":"2026-06-12","current":-27.046231,"twenty":-39.859077,"median":-34.61525,"eighty":-30.390832,"marketCap":8698300410},{"date":"2026-06-18","current":-26.187923,"twenty":-39.726813,"median":-33.720381,"eighty":-29.853022,"marketCap":8442468045},{"date":"2026-06-26","current":-23.913403,"twenty":-39.627323,"median":-32.945231,"eighty":-29.564677,"marketCap":7671559851},{"date":"2026-07-03","current":-27.120201,"twenty":-39.476172,"median":-32.527699,"eighty":-28.324896,"marketCap":8706828155},{"date":"2026-07-10","current":-25.658884,"twenty":-39.120404,"median":-32.474833,"eighty":-27.529192,"marketCap":8227568858},{"date":"2026-07-17","current":-25.917703,"twenty":-38.802803,"median":-32.09845,"eighty":-26.657872,"marketCap":8340135099},{"date":"2026-07-24","current":-28.402389,"twenty":-38.680546,"median":-32.07594,"eighty":-26.891702,"marketCap":9141743176},{"date":"2026-07-31","current":-24.94248,"twenty":-38.662044,"median":-31.566896,"eighty":-26.553964,"marketCap":8043369555},{"date":"2026-08-07","current":-27.580979,"twenty":-37.939269,"median":-30.913769,"eighty":-26.515913,"marketCap":8911494047},{"date":"2026-08-14","current":-27.888785,"twenty":-37.902214,"median":-30.842167,"eighty":-26.553964,"marketCap":9022354739},{"date":"2026-08-21","current":-28.090305,"twenty":-37.770699,"median":-30.35874,"eighty":-26.553964,"marketCap":9107632194},{"date":"2026-08-28","current":-53.27383,"twenty":-37.770699,"median":-30.842167,"eighty":-26.562391,"marketCap":10540293438}],"updateTime":1788185618431},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1130407819","title":"RIBOLIFE-B Reports 2025 Revenue of Approximately 1.485 Billion Yuan, Up 4.1% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1130407819","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130407819?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:43","pubTimestamp":1774449788,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced its 2025 financial results, achieving revenue of approximately 1.485 billion yuan, representing a 4.1% increase compared to the previous year. Gross profit reached about...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164454835","title":"RIBOLIFE-B Appoints Anders Gabrielsen as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=1164454835","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164454835?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:42","pubTimestamp":1774449767,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced the appointment of Dr. Anders Gabrielsen as Chief Medical Officer. Dr. Gabrielsen will oversee the company's overall clinical development, medical affairs, and regulatory...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147245685","title":"Ribo Life Science Names New Chief Medical and Business Officers, Effective 25 March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1147245685","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147245685?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:41","pubTimestamp":1774449667,"startTime":"0","endTime":"0","summary":"On 25 March 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced senior management changes aimed at strengthening its global clinical and commercial operations. Dr. Anders...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622072652","title":"Suzhou Ribo Life Science Co Ltd -  FY Revenue RMB148.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072652","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072652?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:30","pubTimestamp":1774449009,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D0XQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622725680","title":"Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622725680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622725680?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:29","pubTimestamp":1774448990,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science posted FY2025 loss before tax that widened 10.7% to RMB285 million.FY2025 administrative expenses jumped 28% to RMB118 million on higher listing expenses and increased professional and consulting service fees.FY2025 loss per share widened to RMB2.11 from RMB2.10.FY2025 revenue rose 4.1% to RMB149 million on higher collaboration revenue from the Boehringer Ingelheim agreement and higher sales of nucleoside monomers-related products.FY2025 gross profit climbed 3.3% to RMB135 million, while gross profit margin fell 0.8 percentage points to 90.9%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Infor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLFDTsT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620381687","title":"Suzhou Ribo Life Science Attends RNA Leaders Europe Conference in Vienna","url":"https://stock-news.laohu8.com/highlight/detail?id=2620381687","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620381687?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:33","pubTimestamp":1774006383,"startTime":"0","endTime":"0","summary":"Ribo attended the RNA Leaders Europe conference in Vienna, where it delivered a presentation.The company discussed its RiboPepSTAR platform for targeted delivery of siRNA therapies to organs outside the liver.Ribo said preclinical studies showed up to 80% target gene expression reduction in kidney proximal tubular cells.Ribo reported a 96% gene expression reduction in adipose tissue in non-human primates.Ribo said RiboGalSTAR has supported seven clinical programs and partnerships valued at more than USD 6 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via PR Newswire  on March 20, 2026, and is solely responsible for the informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL7X0SXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620144844","title":"Suzhou Ribo Life Science to present ex-hepatic siRNA delivery data at RNA Leaders Europe Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620144844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620144844?lang=en_us&edition=fundamental","pubTime":"2026-03-17 11:00","pubTimestamp":1773716414,"startTime":"0","endTime":"0","summary":"Ribo is scheduled to speak at the RNA Leaders Europe Conference in Vienna, Austria on March 19, 2026. Event materials are available at .","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9GWGgm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166601011","title":"RIBOLIFE-B (06938) Sets 25 Mar 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1166601011","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166601011?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:02","pubTimestamp":1773309771,"startTime":"0","endTime":"0","summary":"According to the announcement released by Suzhou Ribo Life Science Co., Ltd. (stock code: 06938, “RIBOLIFE-B”), the Board of Directors will convene on Wednesday, 25 March 2026. The agenda includes:...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618180268","title":"Suzhou Ribo Life Science to hold board meeting to approve 2025 annual results and consider final dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2618180268","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618180268?lang=en_us&edition=fundamental","pubTime":"2026-03-12 17:52","pubTimestamp":1773309136,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science will hold a board meeting on March 25, 2026 to consider and approve the group’s annual results for the year ended December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL5Y8m4k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197218581","title":"RIBOLIFE-B (06938) Announces Increase in Issued H Shares Following Over-Allotment Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=1197218581","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197218581?lang=en_us&edition=fundamental","pubTime":"2026-03-05 17:51","pubTimestamp":1772704304,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (Stock Code: 06938, RIBOLIFE-B) disclosed monthly return information for the period ended February 28, 2026. The total issued H shares rose from 165.81 million to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176092556","title":"Citigroup Initiates Coverage on RIBOLIFE-B with Buy Rating, Sets HK$102 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1176092556","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176092556?lang=en_us&edition=fundamental","pubTime":"2026-03-05 15:33","pubTimestamp":1772695993,"startTime":"0","endTime":"0","summary":"Citigroup has issued a research report stating that RIBOLIFE-B (06938) is a leading enterprise in the siRNA field, possessing core advantages such as a differentiated drug pipeline and an advanced...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1162221912.USD","BK4534","C","LU1267930227.SGD","LU1244550221.USD","LU0980610538.SGD","LU0098860793.USD","LU0320765646.SGD","LU0648001328.SGD","LU1244550577.SGD","LU2462157665.USD","LU0310800965.SGD","BK4207","BK4588","LU0052756011.USD","LU0072461881.USD","LU0170899867.USD","LU2417539215.USD","LU1668664300.SGD","LU0130102774.USD","IE00BSNM7G36.USD","BK1161","LU0128525689.USD","BK4566","BK4585","LU0162691827.USD","LU1244550494.USD","LU2456880835.USD","LU2360032135.SGD","LU2125154778.USD","06938","LU0130517989.USD","LU0106831901.USD","LU0477156953.USD","LU2236285917.USD","BK4504","LU2125154935.USD","LU1201861249.SGD","LU1791807156.HKD","BK4559","LU1506573853.SGD","LU0314106906.USD","LU1366192091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616016068","title":"Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616016068","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616016068?lang=en_us&edition=fundamental","pubTime":"2026-03-02 11:56","pubTimestamp":1772423773,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science  said a phase 3 clinical of RBD7022 is about to begin after the drug's collaborator, Qilu Pharmaceutical, completed public registration, according to a Hong Kong bourse filing Monday.The drug will be studied as a treatment for high cholesterol to reduce the risk of heart disease.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108221887","title":"Suzhou Ribo Life Science (6938) Announces Phase III Clinical Trial Launch for RBD7022 Injection in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1108221887","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108221887?lang=en_us&edition=fundamental","pubTime":"2026-03-02 09:22","pubTimestamp":1772414532,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (6938) announced that RBD7022 Injection, independently developed by the Group, will begin a Phase III clinical trial after completing public registration by...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132294830","title":"RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=1132294830","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132294830?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:18","pubTimestamp":1772410695,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","III","BK4134","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616258877","title":"Suzhou Ribo Life Science Co - Phase Iii Clinical Trial of Rbd7022 Injection for Treatment of Hyperlipidemia to Be Initiated in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2616258877","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616258877?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:09","pubTimestamp":1772410146,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZO04B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616408877","title":"Suzhou Ribo to start China Phase III trial of RBD7022 for hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2616408877","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616408877?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:08","pubTimestamp":1772410127,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co. Ltd. said its collaborator Qilu Pharmaceutical has completed public registration in China for a Phase III clinical trial of RBD7022 Injection, an siRNA drug targeting PCSK9 for the treatment of hyperlipidemia, and the study is expected to be initiated. The company did not report clinical results in the announcement, and no timing for presenting trial results was provided.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL3dWPtQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":96,"code":"91000000","status":"200"}]}}